PZPPF is the Polish Association of Pharma Industry Employers
Twelve companies in the pharmaceutical industry have created and recorded September 2, 2002 the Polish Association of Pharmaceutical Industries and are acting under the structure of the Polish Confederation of Private Employers.
The national association represents manufacturers of generic drugs.
PZPPF aims at protecting the rights and representing the interests of employers before the authorities, government administration, local government, trade unions and bodies of the European Union – that have been recorded in the statutes of the basic objectives of the Association.
The organization conducts lobbying offensive understood as communication with the authorities, with decision-makers at various levels and in different fields: legislative, economic, trade. For privatized firms, and these form the backbone of the Association, the most important thing are the market opportunities for our products.
Contact
02-520 Warsaw ul. Wiśniowa 40b / 4.
Tel +48 22 542 40 80
Website http://www.producencilekow.pl/
Email sekretariat@pzppf.com.pl
Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and…
Cezary Sledziewski, Executive Director of PZPPF, discusses the pros and cons of Poland’s catching up with EU’s rising standards. He argues: “No one currently knows exactly how much these costs…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
“We have made some progress in terms of the conceptualization of depression as a disease. Previously, the popular attitude was that depression was a temporary emotion; one that could be…
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable. The market size is over 5 billion Euros which makes Poland the 6th biggest market…
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand…
Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of…
As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that.…
Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market…
Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in the internal medicine and…
See our Cookie Privacy Policy Here
